Orphan designation: Fingolimod Treatment of hypomyelinating leukodystrophy-18, 22/05/2023 Positive
Orphan designation: Fingolimod Treatment of hypomyelinating leukodystrophy-18, 22/05/2023 Positive
Orphan designation: Fingolimod Treatment of hypomyelinating leukodystrophy-18, 22/05/2023 Positive
Orphan designation: Efzofitimod Treatment of systemic sclerosis, 20/06/2023 Positive
Orphan designation: Fasudil hydrochloride Treatment of amyotrophic lateral sclerosis, 20/06/2023 Positive
Orphan designation: Adeno-associated virus vector serotype 8 encoding the ABCA4 protein, C-region, adeno-associated virus vector serotype 8 encoding the ABCA4 protein, N-region Treatment of inherited retinal dystrophies, 20/06/2023 Positive
Orphan designation: (3S,3'S,3a'S,10a'S)-6-chloro-3'-(3-chloro-2-fluorophenyl)-1'-(cyclopropylmethyl)-6'-methyl-2-oxo-1,2,3',3a',10',10a'-hexahydro-1'H-spiro[indole-3,2'-pyrrolo[2',3':4,5]pyrrolo[1,2-b]indazole]-7'-carboxylic acid Treatment of soft tissue sarcoma, 20/06/2023 Positive
Orphan designation: Evorpacept Treatment of gastric cancer, 20/06/2023 Positive
Orphan designation: Autologous CD34+ haematopoietic stem and progenitor cells transduced with a lentiviral vector encoding the interferon alpha-2 gene Treatment of glioma, 20/06/2023 Positive
Orphan designation: Autologous dendritic cells pulsed with allogeneic tumour cell lysate Treatment of pancreatic cancer, 20/06/2023 Positive
Orphan designation: exenatide Treatment of moderate and severe closed traumatic brain injury, 20/06/2023 Positive
ACT EU Training for non-commercial sponsors: Transitioning trials to the CTR (CTIS) , Online, European Medicines Agency, Amsterdam, the Netherlands, Broadcast, from 9 February 2024, 10:00 (CET) to 9 February 2024, 13:00 (CET)